Vir Biotechnology (NASDAQ:VIR) Trading Down 3.4% – Here’s What Happened
by Renee Jackson · The Cerbat GemVir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) shares dropped 3.4% on Tuesday . The stock traded as low as $5.83 and last traded at $5.7750. Approximately 264,970 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 1,572,854 shares. The stock had previously closed at $5.98.
Key Vir Biotechnology News
Here are the key news stories impacting Vir Biotechnology this week:
- Positive Sentiment: HC Wainwright raised multiple near‑term and multi‑year EPS forecasts (Q4 2025, Q1–Q4 2026, FY2026–FY2029) and tightened loss estimates — e.g., FY2026 from ($2.40) to ($2.16) and Q4 2025 from ($0.59) to ($0.13) — while reiterating a Buy rating and $15 target. This reduces expected future losses and supports upside to the stock. HC Wainwright note via MarketBeat
- Neutral Sentiment: Media/analyst roundups over the last two days included Vir in lists of analyst-favored biotech names, which can attract attention and flows but doesn’t itself change fundamentals. MSN: 3 ‘Strong Buy’ stocks to buy now
- Negative Sentiment: Quarterly fundamentals remain weak: the company missed Q3/FY results (reported Nov. 5), with large net losses, minimal revenue and highly negative margins — reminders that upside is contingent on clinical/corporate progress or further improvement in guidance. MarketBeat: VIR financials
Analyst Upgrades and Downgrades
VIR has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Monday, December 22nd. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Finally, Evercore ISI started coverage on shares of Vir Biotechnology in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 target price for the company. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Vir Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $17.30.
View Our Latest Stock Analysis on Vir Biotechnology
Vir Biotechnology Trading Up 3.3%
The business’s fifty day simple moving average is $5.99 and its 200 day simple moving average is $5.51. The stock has a market cap of $838.89 million, a P/E ratio of -1.67 and a beta of 1.34.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.47). Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $1.98 million. During the same period in the prior year, the firm posted ($1.56) earnings per share. The company’s revenue was up .8% on a year-over-year basis. On average, analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Vir Biotechnology news, major shareholder Endurance (Cayman) Ltd Svf sold 466,242 shares of the company’s stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $6.05, for a total transaction of $2,820,764.10. Following the transaction, the insider owned 15,621,369 shares of the company’s stock, valued at approximately $94,509,282.45. This represents a 2.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 3,009,666 shares of company stock valued at $18,163,565. Insiders own 16.00% of the company’s stock.
Institutional Trading of Vir Biotechnology
Institutional investors have recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new position in shares of Vir Biotechnology in the 2nd quarter valued at $65,100,000. Cinctive Capital Management LP bought a new stake in Vir Biotechnology in the first quarter valued at about $547,000. Clarius Group LLC increased its holdings in Vir Biotechnology by 979.7% in the second quarter. Clarius Group LLC now owns 617,535 shares of the company’s stock valued at $3,112,000 after purchasing an additional 560,342 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Vir Biotechnology by 43.6% in the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after buying an additional 225,544 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Vir Biotechnology during the second quarter worth about $289,000. Institutional investors and hedge funds own 65.32% of the company’s stock.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.